Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Quinton Oswald
AddedMar 31, 2024
UpdatedMay 31, 2026
Quinton Oswald

Quinton Oswald

Board Member, Okogen

LinkedIn

Quinton Oswald's Career

Okogen
Okogen

Encinitas, CA, US

Board Member· Board
Notal Vision
Notal Vision

Manassas, VA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Quinton Oswald's Career

Okogen
Okogen
Public$16.4M62015Encinitas, CA, US
Board Member· Board

Leadership at Okogen

Brian StremBrian StremFounder & CEO

Similar to Okogen

OculogenexOculogenexLa Habra, CA, USGene Therapyest. 2020OculogenexLa Habra, CA, US · est. 2020

Oculogenex: A biopharmaceutical firm specializing in gene therapy for retinal disorders.

Pre-Seed · $1.3M7
OcugenOcugenMalvern, PA, USGene Therapy, Vaccinesest. 2013OcugenMalvern, PA, US · est. 2013

Ocugen, Inc., a Pennsylvania-based biopharmaceutical firm, specializes in regenerative medicine for joint health.

Public · $206.5M84
OcugenixOcugenixPittsburgh, PA, USImmunotherapy Drugsest. 2015OcugenixPittsburgh, PA, US · est. 2015

Ocugenix develops cancer immunotherapy drugs for eye diseases, combating drug-resistant bacteria.

Seed · $150k5
Surface PharmaceuticalsSurface PharmaceuticalsDelaware, USPharmaceuticalsest. 2017Surface PharmaceuticalsDelaware, US · est. 2017

Delaware-based Surface Pharmaceuticals develops biotech solutions for dry eye diseases, serving California.

Series A · $46.8M8
Notal Vision
Notal Vision
Series D$85M1002000Manassas, VA, US
Board Member· Board

Leadership at Notal Vision

Guy KatsavGuy KatsavBoard Member
Barak AzmonBarak AzmonCo-Founder
Boaz DinteBoaz DinteBoard Member
Yair AlsterYair AlsterCo-Founder
Kester NahenKester NahenCEO

Similar to Notal Vision

NeuroVision ImagingNeuroVision ImagingSacramento, CA, USDiagnostic Testsest. 2010NeuroVision ImagingSacramento, CA, US · est. 2010

NeuroVision develops diagnostic tests and biomarkers for Alzheimer's, using novel retinal imaging tech and data analysis.

Series B · $21.2M12
Insight OpticsInsight OpticsAtlanta, GA, USDiagnostic Toolsest. 2015Insight OpticsAtlanta, GA, US · est. 2015

Insight Optics, a diagnostic startup, uses AI to connect primary care providers with specialists for assisted diagnostics, improving accessibility and disease prevention.

Seed · $930k14
EyenukEyenukWoodland, CA, USDisease Detection, Eye Screeningest. 2010EyenukWoodland, CA, US · est. 2010

Eyenuk, Inc.: A global leader in AI-powered eye disease detection, based in Woodland Hills, US.

Series A · $47.4M30
Aeye HealthAeye HealthNew York City, NY, USAI Diagnosticsest. 2018Aeye HealthNew York City, NY, US · est. 2018

AEYE Health: An FDA-approved digital health startup using AI for autonomous interpretation of fundus images.

Seed · $10M20

Quinton Oswald's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Quinton Oswald

Eric OlsonEric OlsonBoard Member · VishionCasey GordonCasey GordonBoard Member · Supira MedicalRichard EliasRichard EliasBoard Member · Universal DisplayJames SmithJames SmithBoard Member · Hypres